Megakaryocytic Expansion in Gilteritinib-Treated Acute Myeloid Leukemia Patients Is Associated With AXL Inhibition

Numerous recurrent genetic mutations are known to occur in acute myeloid leukemia (AML). Among these common mutations, Fms-like tyrosine kinase 3 remains as one of the most frequently mutated genes in AML. We observed apparent marrow expansion of megakaryocytes in three out of six patients with Flt3-mutated AML following treatment with a recently FDA-approved Flt3 inhibitor, gilteritinib which possesses activity against internal tandem duplication and tyrosine kinase domain Flt3 mutations and also inhibits tyrosine kinase AXL. To assess whether biopsy findings can be attributed to promotion of megakaryocytic (Mk) differentiation with gilteritinib, we devised a cellular assay by overexpressing double mutated Flt3-ITDY591F/Y919F in chronic myeloid leukemia cell line K562 to study Mk differentiation in the presence of Flt3 and AXL inhibitors with non-mutually exclusive mechanisms. These experiments demonstrated the lack of direct effect Flt3 inhibitors gilteritinib and quizartinib on megakaryocytic differentiation at either transcriptional or phenotypic levels, and highlighted antileukemic effects of AXL receptor tyrosine kinase inhibitor and its potential role in megakaryocytic development.

[1]  C. Ustun,et al.  Erythroid differentiation of myeloblast induced by gilteritinib in relapsed FLT3-ITD-positive acute myeloid leukemia. , 2019, Blood advances.

[2]  R. Larson,et al.  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. , 2019, The New England journal of medicine.

[3]  R. Moriggl,et al.  The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis , 2019, Haematologica.

[4]  M. Carroll,et al.  Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. , 2019, Blood advances.

[5]  H. Hayashi,et al.  A β1-tubulin-based megakaryocyte maturation reporter system identifies novel drugs that promote platelet production. , 2018, Blood advances.

[6]  S. Constantinescu,et al.  Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer , 2018, Leukemia.

[7]  Maria R. Baer,et al.  FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions , 2017, Molecular Cancer Therapeutics.

[8]  K. Mori,et al.  Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia , 2017, Investigational New Drugs.

[9]  I. Slukvin,et al.  Wnt signaling inhibitor FH535 selectively inhibits cell proliferation and potentiates imatinib-induced apoptosis in myeloid leukemia cell lines , 2017, International Journal of Hematology.

[10]  Brian E. McIntosh,et al.  Discovery of survival factor for primitive chronic myeloid leukemia cells using induced pluripotent stem cells , 2015, Stem cell research.

[11]  Rui Huang,et al.  Megakaryocytic Differentiation of K562 Cells Induced by PMA Reduced the Activity of Respiratory Chain Complex IV , 2014, PloS one.

[12]  E. Forsberg,et al.  Flk2/Flt3 promotes both myeloid and lymphoid development by expanding non-self-renewing multipotent hematopoietic progenitor cells. , 2014, Experimental hematology.

[13]  P. Carmeliet,et al.  Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. , 2013, Blood.

[14]  M. Caligiuri,et al.  Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. , 2013, Blood.

[15]  U. Zanger,et al.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the “Missing Heritability” Problem , 2013, Front. Genet..

[16]  Bengt Phung,et al.  Suppressor of Cytokine Signaling 6 (SOCS6) Negatively Regulates Flt3 Signal Transduction through Direct Binding to Phosphorylated Tyrosines 591 and 919 of Flt3* , 2012, The Journal of Biological Chemistry.

[17]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[18]  K. Mrózek,et al.  Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. , 2011, Hematology/oncology clinics of North America.

[19]  Frank J T Staal,et al.  Canonical wnt signaling regulates hematopoiesis in a dosage-dependent fashion. , 2011, Cell stem cell.

[20]  M. Ono,et al.  GSK-3β negatively regulates megakaryocyte differentiation and platelet production from primary human bone marrow cells in vitro , 2011, Platelets.

[21]  K. Döhner,et al.  Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. , 2009, Blood.

[22]  Yu-Jen Chen,et al.  Oral small-molecule tyrosine kinase inhibitor midostaurin (PKC412) inhibits growth and induces megakaryocytic differentiation in human leukemia cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[23]  T. Haferlach,et al.  Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. , 2009, Blood.

[24]  Daishu Han,et al.  The role of Tyro 3 subfamily receptors in the regulation of hemostasis and megakaryocytopoiesis. , 2007, Haematologica.

[25]  S. Bohlander,et al.  Block of C/EBPα function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations , 2006, The Journal of experimental medicine.

[26]  Lina A. Thoren,et al.  Identification of Flt3+ Lympho-Myeloid Stem Cells Lacking Erythro-Megakaryocytic Potential A Revised Road Map for Adult Blood Lineage Commitment , 2005, Cell.

[27]  S. E. Jacobsen,et al.  Identification of Lin(-)Sca1(+)kit(+)CD34(+)Flt3- short-term hematopoietic stem cells capable of rapidly reconstituting and rescuing myeloablated transplant recipients. , 2005, Blood.

[28]  M. Levis,et al.  FLT3: ITDoes matter in leukemia , 2003, Leukemia.

[29]  W. Hiddemann,et al.  Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  W. Berdel,et al.  Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. , 2000, Blood.

[31]  C. Shelly,et al.  K562 cells resistant to phorbol 12-myristate 13-acetate-induced growth arrest: dissociation of mitogen-activated protein kinase activation and Egr-1 expression from megakaryocyte differentiation. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[32]  I. Weissman,et al.  A clonogenic common myeloid progenitor that gives rise to all myeloid lineages , 2000, Nature.

[33]  T. Naoe,et al.  Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.

[34]  R. Herrera,et al.  A role for the MEK/MAPK pathway in PMA-induced cell cycle arrest: modulation of megakaryocytic differentiation of K562 cells. , 1998, Experimental cell research.

[35]  S. Goueli,et al.  Sustained Activation of the Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway Is Required for Megakaryocytic Differentiation of K562 Cells* , 1997, The Journal of Biological Chemistry.

[36]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[37]  T. Mcclanahan,et al.  Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs , 1994, Nature.

[38]  G. Marcucci,et al.  implications for Axl as a potential therapeutic target FLT3 internal tandem duplication in human acute myeloid leukemia: Inhibition of the receptor tyrosine kinase Axl impedes activation of the , 2013 .

[39]  Stuart Moss,et al.  Current Status and Future Directions , 2013 .

[40]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.